Cynosure Group’s DexCom DXCM Stock Holding History

Cynosure Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,690	Closed	-$316K	–	444
2025 Q3	$316K	Hold	4,690	–	–	0.03%	338
2025 Q2	$409K	Sell	4,690 -285	-6%	-$22.3K	0.05%	265
2025 Q1	$340K	Buy	4,975 +1,288	+35%	+$105K	0.05%	261
2024 Q4	$287K	Sell	3,687 -32,545	-90%	-$2.41M	0.04%	306
2024 Q3	$2.43M	Buy	36,232 +33,022	+1,029%	+$2.71M	0.35%	42
2024 Q2	$364K	Buy	3,210 +873	+37%	+$110K	0.06%	308
2024 Q1	$324K	Buy	+2,337	New	+$294K	0.06%	224

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cynosure Group's DXCM Position: Q4 2025 in Review

Cynosure Group sold out of DexCom (DXCM) in Q4 2025, closing a stake of 4,690 shares — an estimated $316K sold.

Cynosure Group first reported a position in DXCM in Q1 2024 and held it in 7 quarters. The position peaked at $2.43M in Q3 2024. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Cynosure Group reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Cynosure Group sold 4,690 DexCom shares in Q4 2025, an estimated $316K.
Cynosure Group first reported a position in DexCom in Q1 2024 and held it in 7 quarters.
Cynosure Group's DexCom position peaked at $2.43M in Q3 2024.
921 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Cynosure Group's 13F filing for Q4 2025, filed 17 Feb 2026.